Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

959 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.
Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, Holgate ST, Picado C, Menten J, Dass SB, Leff JA, Polos PG. Bjermer L, et al. Among authors: holgate st. BMJ. 2003 Oct 18;327(7420):891. doi: 10.1136/bmj.327.7420.891. BMJ. 2003. PMID: 14563743 Free PMC article. Clinical Trial.
Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, Lumry WR, Picado C, Stevenson DD, Bousquet J, Pauwels R, Holgate ST, Shahane A, Zhang J, Reiss TF, Szczeklik A. Dahlén SE, et al. Among authors: holgate st. Am J Respir Crit Care Med. 2002 Jan 1;165(1):9-14. doi: 10.1164/ajrccm.165.1.2010080. Am J Respir Crit Care Med. 2002. PMID: 11779723 Clinical Trial.
Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening A, Haahtela T, Holgate ST, Picado C, Leff JA. Bjermer L, et al. Among authors: holgate st. Respir Med. 2000 Jun;94(6):612-21. doi: 10.1053/rmed.2000.0806. Respir Med. 2000. PMID: 10921768 Free article. Clinical Trial.
Asthma control or severity: that is the question.
Humbert M, Holgate S, Boulet LP, Bousquet J. Humbert M, et al. Allergy. 2007 Feb;62(2):95-101. doi: 10.1111/j.1398-9995.2006.01308.x. Allergy. 2007. PMID: 17298415 Review.
Summary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma.
Holgate ST, Bousquet J, Chung KF, Bisgaard H, Pauwels R, Fabbri L, Rabe K, Doherty M, Snell NJ, Cuss F, D'Amato M, Reginster JY; Group for the Respect of Ethics and Excellence in Science: Asthma section. Holgate ST, et al. Respir Med. 2004 Jun;98(6):479-87. doi: 10.1016/j.rmed.2003.12.005. Respir Med. 2004. PMID: 15191031 Free article. Review.
Severe eosinophilic asthma: a roadmap to consensus.
Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, Quirce S, Virchow JC, Holgate S; expert group of the European Consensus Meeting for Severe Eosinophilic Asthma. Buhl R, et al. Eur Respir J. 2017 May 1;49(5):1700634. doi: 10.1183/13993003.00634-2017. Print 2017 May. Eur Respir J. 2017. PMID: 28461308 Free article. No abstract available.
959 results